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Background: Ginkgo biloba extract (GBE)—a widely used nutraceutical—is reported to have diverse func- 
tions, including positive effects on memory and vasodilatory properties. Although numerous studies have 
assessed the neuroprotective properties of GBE in ischemia, only a few studies have investigated the 
neuro-pharmacological mechanisms of action of GBE in chronic cerebral hypoperfusion (CCH). 
Purpose: In the present study, we sought to determine the effects of GBE on CCH-induced neuroinﬂam- 
mation and cholinergic dysfunction in a rat model of bilateral common carotid artery occlusion (BCCAo). 
Methods: Chronic BCCAo was induced in adult male Wistar rats to reﬂect the CCH conditions. On day 21 
after BCCAo, the animals were treated orally with saline or GBE (5, 10, 20, and 40 mg/kg) daily for 42 
days. After the ﬁnal treatment, brain tissues were isolated for the immunohistochemical analysis of glial 
markers and choline acetyltransferase (ChAT), as well as for the western blot analysis of proinﬂammatory 
cytokines, toll-like receptor (TLR)-related pathway, receptor for advanced glycation end products (RAGE), 
angiotensin-II (Ang-II), and phosphorylated mitogen-activated protein kinases (MAPKs). 
Results: BCCAo increased glial proliferation in the hippocampus and white matter, whereas proliferation 
was signiﬁcantly attenuated by GBE treatment. GBE also attenuated the BCCAo-related increases in the 
hippocampal expression of proinﬂammatory cytokines (TNF- α, IL-1 β , and IL-6), TLR4, myeloid differenti- 
ation primary response gene 88, RAGE, Ang-II, and phosphorylated MAPKs (ERK, p38, and JNK). Further- 
more, GBE treatment restored the ChAT expression in the basal forebrain following BCCAo. 
Conclusions: These ﬁndings suggest that GBE has speciﬁc neuroprotective effects that may be useful for 
the treatment of CCH. The pharmacological mechanism of GBE partly involves the modulation of inﬂam- 
matory mediators and the cholinergic system. 
© 2016 The Authors. Published by Elsevier GmbH. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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2  Introduction 
Ginkgo biloba L. (Ginkgoaceae) leaf extract (GBE) is among
the most widely used traditional herbal medicines, and has
been used to treat various diseases including depression, anx-Abbreviations: Ang-II, angiotensin II; BCCAo, Bilateral common carotid artery oc- 
clusion; CCH, chronic cerebral hypoperfusion; ChAT, choline acetyltransferase; DG, 
dentate gyrus; ERK, extracellular signal-regulated kinase; GBE, Ginkgo biloba extract; 
JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; TLR, toll- 
like receptor; RAGE, receptor for advanced glycation end products; VaD, vascular 
dementia. 
∗ Corresponding author at: Korea Institute of Oriental Medicine, 1672 
Yuseongdae-ro, Yuseong-gu, Daejeon 34054, Republic of Korea. 
E-mail address: wkjeon@kiom.re.kr (W.K. Jeon). 
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http://dx.doi.org/10.1016/j.phymed.2016.07.013 
0944-7113/© 2016 The Authors. Published by Elsevier GmbH. This is an open access articl
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). ety, headache, and memory impairment in Asia and Europe
 Shah et al., 2011; Zhang et al., 2012 ). With regard to composition,
avonoids—such as lipoxygenase and phospholipase A2—comprise
2–27% of GBE, whereas terpene lactones—including ginkgolides A,
, C, J, and bilobalide—comprise 5–7% of GBE ( Kwak et al., 2012 ).
o date, experimental evidence has indicated that GBE is a useful
herapeutic agent for disorders of cerebral circulation ( Zhang et al.,
012 ). Moreover, GBE treatment has been reported to alleviate hip-
ocampal neuronal death following transient global ischemia via
nti-inﬂammatory and anti-oxidative mechanisms ( Tulsulkar and
hah, 2013 ), and has also been shown to improve memory deﬁcits
fter transient ischemia in object location ( Rocher et al., 2011 ) and
versive radial maze tasks ( Paganelli et al., 2006 ). e under the CC BY-NC-ND license 
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t  The majority of evidence for the protective effects of GBE on
essel occlusion is derived from models of ischemia that mimic
troke. In addition to stroke, chronic cerebral hypoperfusion (CCH)
s another serious disorder that is typically aging-related and can
esult in vascular dementia (VaD) ( Lana et al., 2014 ). However,
nlike stroke, which leads to severe focal brain damage, CCH re-
ults in mild global damage over time ( Farkas et al., 2007 ). Hence,
CH models are typically used to investigate the long-term effects
f vessel occlusion. By using a CCH model, previous studies have
hown that GBE treatment resolved memory impairments, as mea-
ured by the Morris water maze ( Li et al., 2013 ) and the eight-arm
adial maze ( Kwak et al., 2012 ); in fact, these effects were found
o be associated with the inhibition of apoptosis and oxidative re-
ponse. 
The most commonly observed characteristics of CCH pathol-
gy are neuroinﬂammation and cholinergic deﬁciency ( Choi et al.,
011 ); however, the effects of GBE on inﬂammatory responses and
holinergic dysfunction in CCH remain unclear. A recent study
howed that GBE prevents the development of lung inﬂammatory
esponses, induced by lipopolysaccharide, by inhibiting NF-kB-p65
nd Cox-2 ( Xin et al., 2015 ). In addition, cholinergic neurotransmis-
ion in the rat medial prefrontal cortex was found to be enhanced
y treatment with GBE and its ﬂavonol derivatives ( Kehr et al.,
012 ). Because GBE has protective effects against inﬂammation and
holinergic dysfunction, it is also expected to be able to treat re-
ated symptoms observed in CCH. 
Therefore, in the present study, we aimed to examine the im-
act of GBE on inﬂammation and cholinergic deﬁcits related to
CH. We induced permanent bilateral common carotid artery oc-
lusion (BCCAo) in rats to establish a CCH model, which is a widely
sed preclinical model for VaD therapeutic screening ( Kwon et al.,
014 ). BCCAo rats were orally dosed with GBE extracted from
inkgo biloba leaves (commercial name: Tanasol solution [Yuyu
harmaceutical company, Seoul, Korea]), and the glial populations
ere evaluated in the white matter and hippocampus, which are
egions vulnerable to CCH ( Ueno et al., 2015 ). Thereafter, we in-
estigated the protective effects of GBE in BCCAo by studying the
xpression of toll-like receptor (TLR) pathways and choline acetyl-
ransferase (ChAT). To our knowledge, the present study is the ﬁrst
uch evaluation on this topic and provides important mechanistic
nsights into the therapeutic beneﬁts of GBE in CCH. 
aterials and methods 
nimals 
All the procedures described in this study were approved by the
nstitutional Animal Care and Use Committee of the Korea Institute
f Oriental Medicine (KIOM) (permit number: 15-018). Male Wistar
ats (280 ± 10 g, 12 weeks) were obtained commercially (Charles
iver Co., Gapyung, South Korea). For 2 weeks prior to the ex-
eriment, rats were housed in a vivarium at the KIOM, in an en-
ironment with controlled temperature (22 ± 1 °C) and humidity
55 ± 10%), on a 12-h light/dark cycle, with water and food avail-
ble ad libitum . 
urgery 
Rats were anesthetized with 5% isoﬂurane in a mixture of 30%
xygen/70% nitrogen and a modiﬁed BCCAo surgery was performed
 Choi et al., 2011 ). Brieﬂy, a skin incision was made to expose
oth the common carotid arteries, which were then separated from
he vagus nerve and its sheath. Both arteries were tightly double-
igated with 4-0 silk sutures and the incision was closed. The sham
roup underwent the same procedure without carotid artery lig-
tion. During the surgical procedure, the body temperature wasonitored and maintained at 37.0 ± 0.5 °C and all effort s were
ade to minimize pain and distress. 
harmacological treatment 
Ginkgo biloba L. is an accepted plant name, and is listed in The
lant List ( www.theplantlist.org ). Tanasol Solution (40 mg/20 ml
iquid bottle, batch number 150253, Yuyu Pharmaceutical Com-
any, Seoul, Korea)—a commercial drug containing GBE—was used
n this study. The drug:genuine extract ratio (DER) was between
5:1 and 67:1. As stated by the manufacturer, the drug contains
 major components: quercetin (229.11 ± 5.06 μg/ml), kaempferol
224.01 ± 1.37 μg/ml), and isorhamnetin (52.88 ± 4.55 μg/ml); these
omponents are the principal ﬂavonoids in Ginkgo biloba and
re listed as marker compounds for quality control in the Ko-
ean pharmacopeia. All the rats were randomly assigned to 1
f 6 treatment groups: (1) sham-operated + saline ( n = 12), (2)
CCAo + saline ( n = 12), (3) BCCAo + GBE 5 mg/kg ( n = 12), (4)
CCAo + GBE 10 mg/kg ( n = 12), (5) BCCAo + GBE 20 mg/kg ( n = 12),
r (6) BCCAo + GBE 40 mg/kg ( n = 12). GBE and vehicle were ad-
inistered daily via oral gavage from 21 days after surgery to 63
ays after surgery (treatment period, 42 days). The dose range of
BE was determined based on previous reports ( Kwak et al., 2012;
ooshinfar et al., 2008 ). Animals were sacriﬁced at 63 days after
urgery and tissues were collected for analysis. 
mmunohistochemical analysis 
The immunohistochemical analysis of glial ﬁbrillary acidic pro-
ein (GFAP), ionized calcium binding adaptor molecule-1 (Iba-1),
nd ChAT was performed to determine the number of astrocytes,
icroglia, and cholinergic neurons, respectively. Whole brains were
mmersed in 4% paraformaldehyde for 3 days, cryoprotected in 30%
ucrose, and then stored at −70 °C until use. Brain cryosections
40 μm) were prepared and incubated with GFAP (Abcam, CA, USA),
ba-1 (Wako, Tokyo, Japan), or ChAT (Millipore, MA, USA) primary
ntibodies in phosphate buffered saline (PBS) containing 3% casein
nd 0.1% Triton-X 100 overnight at 4 °C. After washing with PBS,
he tissues were incubated with anti-rabbit IgG secondary antibody
Cell Signaling, MA, USA). Tissues were subsequently exposed to a
ector SG substrate kit and a Vector DAB kit (Vector Laboratories,
A, USA) for peroxidase staining, and then mounted onto resin-
oated slides by using Permount reagent (Fisher Scientiﬁc, PA,
SA). All immunoreactions were examined using light microscopy
Bx 51; Olympus, Japan), and the number of cells stained positive
or Iba-1 and GFAP was assessed in speciﬁc regions (0.03 mm 2 ) of
hite matter (the corpus callosum, ﬁmbria, and optic tract) and
he hippocampus (CA1, CA3, and dentate gyrus [DG]). The number
f ChAT-positive neurons was quantiﬁed in regions (0.03 mm 2 ) of
he basal forebrain. A minimum of 3 sections were selected per rat
nd averaged for quantiﬁcation. 
estern blot analysis 
Western blot was performed as previously described with
ome modiﬁcations ( Kim et al., 2015 ). Brieﬂy, hippocampal tis-
ue was dissected and homogenized in cold lysis buffer contain-
ng 25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% nonyl phenoxy-
olyethoxylethanol, 1% sodium deoxycholate, 0.1% sodium dode-
yl sulfate, (Thermo Scientiﬁc, MA, USA), and protease and phos-
hatase inhibitor cocktail solutions (GenDEPOT, TX, USA). Ho-
ogenates were centrifuged at 20,0 0 0 × g for 30 min at 4 °C,
nd the supernatants were collected and stored at −70 °C un-
il use. Protein concentrations were determined by using Brad-
ord’s reagent (Bio-Rad, CA, USA), and equivalent amounts of pro-
ein (40 μg) were electrophoresed by using SDS-PAGE. The proteins
1358 M.-S. Kim et al. / Phytomedicine 23 (2016) 1356–1364 
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t  were transferred to a PVDF membrane and blocked in 5% dry non-
fat milk for 1 h at room temperature, followed by overnight incu-
bation at 4 °C with the following primary antibodies: tumor necro-
sis factor alpha (TNF- α, Santa Cruz, CA, USA); interleukin-1 beta
(IL-1 β , Millipore); IL-6 (Abcam); TLR2 (Santa Cruz); TLR4 (Santa
Cruz); myeloid differentiation factor 88 (MyD88, Santa Cruz);
Toll/IL-1R domain–containing adaptor-inducing IFN- β (TRIF, Santa
Cruz); receptor for advanced glycation end products (RAGE, Ab-
cam); angiotensin-II (Ang-II, Abcam); extracellular signal-regulated
kinase (ERK, Cell signaling); p38 MAPK (Cell Signaling); and c-
Jun N-terminal kinases (JNK, Cell Signaling). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, Santa Cruz) was used as the
internal loading control. After primary incubation, the membranes
were washed and incubated with goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Cell Signaling). West-
ern blots were visualized by using an ECL system (Thermo Sci-
entiﬁc) with a Lumino Image Analyzer (Las-40 0 0; Fujiﬁlm, Tokyo,
Japan). The densitometric values of the bands of interest were nor-
malized to the GAPDH values by using Multi Gauge software (Fuji-
ﬁlm). 
Statistical analysis 
All data are expressed as mean ± standard deviation. The data
shown are the average of 2 independent replicate experiments.
For statistical analysis, the homogeneity of variances was tested
by Levene’s test. Between-group comparisons were performed by
using a one-way ANOVA with a post hoc test (the Least Signif-
icant Difference test), and p -values ≤0.05 were considered to be
statistically signiﬁcant. If the variances were not homogeneous, a
Tamhane test was applied as a post-hoc test. To detect a dose-
related effect, a regression with linear trend estimation was used.
All the statistical analyses were performed using SPSS 20.0 soft-
ware (IBM, IL, USA). 
Results 
Effects of GBE on the glia in the hippocampus and white matter 
A common feature of the BCCAo rat model is glial (microglia
and astrocytes) proliferation ( Bang et al., 2013; Cai et al., 2010;
Cho et al., 2006 ). Therefore, we quantiﬁed the Iba-1- and GFAP-
positive cells in the hippocampal subregions (including the CA1,
CA3, and DG cells) as well as the major white matter regions
of the brain (including the corpus callosum, ﬁmbria, and optic
tract). The number of Iba-1-positive cells was estimated to indi-
cate the number of microglia ( Fig. 1 ). A one-way ANOVA revealed
signiﬁcant between-group effects in all the regions investigated
(F (5,30) ≥ 10.446, p < 0.001). The number of microglia in the hip-
pocampus and white matter was signiﬁcantly greater in the BCCAo
group than in the sham group (### p < 0.001; Fig. 1 A-D). How-
ever, the administration of GBE attenuated the BCCAo-induced mi-
croglial proliferation in the hippocampus and white matter, par-
ticularly at a dose of 40 mg/kg ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001;
Fig. 1 A-D). The number of microglia in the BCCAo + GBE 40 mg/kg
group was not signiﬁcantly different from that in the sham group.
GBE exhibited the dose-related inhibition of microglial prolifera-
tion. 
The number of GFAP-positive cells was also estimated to re-
ﬂect the number of astrocytes in the hippocampus and white
matter regions ( Fig. 2 ). A one-way ANOVA showed that the ef-
fects between groups were signiﬁcant in all the regions inves-
tigated (F (5,30) ≥ 5.192, p < 0.002). Post-hoc analyses revealed that
the number of astrocytes was signiﬁcantly greater in the BCCAo
group than in the sham group, and decreased following GBE treat-
ment after BCCAo, particularly at a dose of 40 mg/kg ( ∗p < 0.05,∗p < 0.01, ∗∗∗p < 0.001; Fig. 2 A-D). GBE exhibited the dose-related
nhibition of astrocytic proliferation. These results indicate that
BE inhibits the BCCAo-induced glial proliferation in the hip-
ocampus and white matter. 
ffects of GBE on the levels of hippocampal proinﬂammatory 
ytokines 
Previous studies have reported that glia secrete proinﬂamma-
ory cytokines in pathological conditions ( Smith et al., 2012; Ya-
uda et al., 2011 ). To investigate the effects of GBE on the increased
evels of proinﬂammatory cytokines, the levels of TNF- α, IL-1 β ,
nd IL-6 were measured in the hippocampus. A one-way ANOVA
evealed signiﬁcant between-group effects for the expression levels
f proinﬂammatory cytokines (F (5,30) ≥ 4.812, p< 0.002). Accord-
ng to post-hoc analyses, the expression of TNF- α, IL-1 β , and IL-
 was greater in the hippocampus of the BCCAo group than in
he sham group (## p < 0.01, ### p < 0.001; Fig. 3 A-B). Importantly,
he BCCAo-related increases in hippocampal cytokine expression
ere attenuated by GBE treatment at doses of 20 and 40 mg/kg
 
∗∗p < 0.01, ∗∗∗p < 0.001; Fig. 3 A-B). GBE also showed dose-related
ffects in mitigating increases in hippocampal proinﬂammatory cy-
okines after BCCAo. 
ffects of GBE on the hippocampal TLR4 pathway 
Thereafter, we investigated whether GBE affected TLR signal-
ng, which is known to play an important role in glial-derived
euroinﬂammation ( Yao et al., 2013 ). A one-way ANOVA re-
ealed signiﬁcant between-group effects for the expression of TLR4
F (5,30) = 7.641, p < 0.001), but not TLR2 (F (5,30) = 1.783, p = 0.147),
n the hippocampus. Treatment with GBE at a dose of 40 mg/kg
uppressed the BCCAo-related increases in hippocampal TLR4 ex-
ression, in a dose-related manner ( ∗∗p < 0.01; Fig. 4 A, 4 D). We
urther investigated the hippocampal expression of TLR4 down-
tream mediators, TRIF and MyD88 ( Tanimura et al., 2008 ). One-
ay ANOVA showed signiﬁcant effects between groups for the
yD88 levels (F (5,30) = 15.228, p < 0.001), but not for the TRIF lev-
ls (F (5,30) = 1.723, p = 0.160). GBE treatment attenuated the BCCAo-
elated increases in MyD88 expression at doses of 20 and 40 mg/kg
n a dose-related manner ( ∗∗∗p < 0.001; Fig. 4 B, 4 E). These results
uggest that GBE alleviates the BCCAo-related changes in the TLR4-
yD88-dependent pathway in rats. 
ffects of GBE on the hippocampal expression of RAGE and Ang-II 
RAGE and Ang-II are known to elicit the production of proin-
ammatory cytokines in the CNS ( Agarwal et al., 2013; Srikanth
t al., 2011 ). Therefore, we investigated the effect of GBE on the
xpression of RAGE and Ang-II in the hippocampus. A one-way
NOVA revealed signiﬁcant between-group effects for the expres-
ion of RAGE (F (5,30) = 3.605, p = 0.011) and Ang-II (F (5,30) =2.493,
 = 0.047). According to the post-hoc analyses, GBE treatment at a
ose of 40 mg/kg inhibited the BCCAo-induced increases in RAGE
nd Ang-II expression ( ∗p < 0.05, ∗∗p < 0.01; Fig. 4 C and F); how-
ver, the reduction did not appear to be dose-related. 
ffects of GBE on the hippocampal expression of MAPK pathway 
omponents 
Moreover, we investigated the effect of GBE on MAPK signal-
ng, which is known to regulate the cellular inﬂammatory re-
ponse ( Lin et al., 2012 ). We speciﬁcally examined the phos-
horylation status of ERK, p38, and JNK in the hippocampus. A
ne-way ANOVA revealed signiﬁcant between-group effects for
he phosphorylation of ERK (F (5,30) =6.386, p < 0.001) and p38
M.-S. Kim et al. / Phytomedicine 23 (2016) 1356–1364 1359 
Fig. 1. GBE inhibits BCCAo-induced microglial proliferation in subregions of the hippocampus and white matter. (A and B) Representative Iba-1 staining in the hippocampal 
CA1, CA3, and dentate gyrus (DG) subregions (A) and in the corpus callosum, ﬁmbria, and optic tract (B). (C and D) Measurement of the absolute numbers of Iba-1-positive 
microglia ( n = 6). ### p < 0.001 compared with sham plus vehicle; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared with BCCAo plus vehicle. Original magniﬁcation was 40 × for 
the entire hippocampus and 200 × for other regions. 
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t  F (5,30) ≥ 8.873, p < 0.001), but not JNK (F (5,30) = 0.581, p = 0.714).
he total levels of ERK, p38, and JNK were unaffected by GBE
reatment. As assessed by western blotting and further analyzed
n post-hoc analyses, GBE treatment, particularly at a dose of
0 mg/kg, attenuated the BCCAo-induced changes in the phospho-
ylation status of ERK and p38 ( ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001;
ig. 5 A-B), and showed a dose-related effect. 
ffects of GBE on ChAT expression in the medial septum 
Cholinergic dysfunction has been reported to develop in BCCAo
ats ( Choi et al., 2011 ), and has been found to be closely related
o MAPK alterations in the brain ( Williams et al., 2007 ). To ex-
mine the effects of GBE on cholinergic neurons, the number of
hAT-positive cells in the basal forebrain was estimated by using
mmunohistochemistry. Signiﬁcant group effects were observed in
he expression of ChAT (F (5,30) =23.307, p < 0.001). Post-hoc anal-
ses revealed that the number of ChAT-positive cells in the basalorebrain was lower in the BCCAo group than in the sham group
### p < 0.001; Fig. 6 A-B). However, the reduction in the num-
er of ChAT-positive cells was signiﬁcantly resolved by GBE treat-
ent at doses of 20 and 40 mg/kg ( ∗p < 0.05, ∗∗∗p < 0.001; Fig. 6 A-
), and exhibited dose-related effects. These results indicate that
BE treatment may be neuroprotective for cholinergic neurons in
CCAo-induced CCH. 
iscussion 
CCH leads to working and reference memory impairments and
hite matter injury that resemble VaD ( Jiwa et al., 2010 ). Although
aD is the second most common cause of dementia, no widely ac-
epted treatment or cure is currently available ( Guerra et al., 2015 ).
iven that the number of VaD patients is increasing in various ag-
ng societies, several studies have focused on novel therapeutic and
reventative approaches for VaD, as well as better diagnostic cri-
eria ( Kalaria, 2016 ). To our knowledge, this is the ﬁrst report to
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Fig. 2. GBE inhibits BCCAo-induced astrocyte proliferation in subregions of the hippocampus and white matter. (A and B) Representative GFAP staining in the hippocampal 
CA1, CA3, and dentate gyrus (DG) subregions (A) and in the corpus callosum, ﬁmbria, and optic tract (B). (C and D) Measurement of the absolute numbers of GFAP-positive 
astrocytes ( n = 6). ### p < 0.001 compared with sham plus vehicle; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared with BCCAo plus vehicle. Original magniﬁcation was 40 × for 
the entire hippocampus and 200 × for other regions. 
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c  show that GBE treatment ameliorates various pathological changes
in the hippocampus and white matter in a rat model of BCCAo-
induced CCH. We found that GBE resolved the CCH-related patho-
logical changes, and accordingly may have therapeutic utility in the
treatment of VaD. 
GBE has traditionally been used for the treatment of age-related
memory dysfunction. Bilobalide, ginkgolide A, ginkgolide B, and
terpenes are thought to be the major active compounds in GBE
that improve memory ( Shah et al., 2011 ). Several studies on CCH
models have demonstrated that GBE and its constituents are neu-
roprotective in nature. The white matter damage induced by BC-
CAo has been found to be attenuated by the administration of
GBE ( Kwak et al., 2012 ). Moreover, bilobalide has been reported
to resolve the cognitive deﬁcits in BCCAo through antioxidant and
anti-apoptotic mechanisms ( Li et al., 2013 ). In addition to oxidative
stress and apoptosis, neuroinﬂammation and cholinergic dysfunc-
tion are the other common features of CCH. These features haveeen insuﬃciently studied in previous studies and were therefore
he subject of our investigation. 
A growing number of studies have reported that BCCAo elic-
ts neuroinﬂammatory responses, including glial proliferation and
he up-regulation of proinﬂammatory cytokines ( Cai et al., 2010;
ee et al., 2013 ). Several studies have assessed the key roles of
lia in neuroinﬂammation following central nervous system injury.
asuda et al. demonstrated that the number of IL-1 β-positive as-
rocytes is increased in the hippocampus 10 min after 4-vessel oc-
lusion ( Yasuda et al., 2011 ). Smith et al. reported that microglial
esponses following neuronal injury or ischemia led to the sub-
equent release of proinﬂammatory cytokines, including IL-1 and
L-6, and may have contributed to neurodegenerative pathology
 Smith et al., 2012 ). Therefore, the inhibition of glial activation is
 promising therapeutic strategy for CCH. In the present study,
e found that GBE, particularly at higher doses, attenuated glial
ell proliferation in the hippocampus and white matter, and re-
M.-S. Kim et al. / Phytomedicine 23 (2016) 1356–1364 1361 
Fig. 3. GBE attenuates BCCAo-induced expression of proinﬂammatory cytokines in the hippocampus. (A) Representative western blots of proinﬂammatory cytokines in 
hippocampal tissues. GAPDH was used as the loading control. (B) Quantitative analysis of cytokine expression/GAPDH intensity ( n = 6). ## p < 0.01, ### p < 0.001 compared 
with sham plus vehicle; ∗∗p < 0.01, ∗∗∗p < 0.001 compared with BCCAo plus vehicle. 
Fig. 4. GBE down-regulates the expression of TLR-related proteins, RAGE, and Ang-II following chronic BCCAo in the hippocampus. (A-C) Representative western blots of 
TLR2, TLR4, MyD88, TRIF, RAGE, and Ang-II in hippocampal tissues. GAPDH was used as the loading control. (D-F) Quantitative analysis of protein expression/GAPDH intensity 
( n = 6). # p < 0.05, ## p < 0.01, ### p < 0.001 compared with sham plus vehicle; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared with BCCAo plus vehicle. 
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s  uced hippocampal proinﬂammatory cytokine production after BC-
Ao. Importantly, we decided to administer GBE orally to maxi-
ize the translational nature of our study, and initiated treatment
n post-surgical day 21, based on the ﬁndings of a previous study
herein day 21 was estimated as the time of peak neuroinﬂam-
ation after BCCAo ( Bang et al., 2013 ). Our results support the hy-
othesis that GBE exerts an anti-inﬂammatory effect by inhibiting
lial cell proliferation and activation. h  To study the molecular mechanisms of the anti-inﬂammatory
ffect of GBE in CCH, we evaluated the expression of TLRs and TLR
ignaling-related proteins in the hippocampus. TLRs were found
o be key target receptors for the innate immune response and
roinﬂammatory cytokine production ( Kawasaki and Kawai, 2014 ).
n particular, TLR4 has been frequently cited in relation to neu-
oinﬂammation in the literature ( Caso et al., 2007 ). In the present
tudy, we found that GBE administration markedly down-regulated
ippocampal TLR4 and MyD88 after BCCAo. These results suggest
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Fig. 5. GBE inhibits BCCAo-induced MAPK phosphorylation in the hippocampus. (A) Representative western blots of unphosphorylated and phosphorylated ERK, p38, and 
JNK in hippocampal tissues. (B) Quantitative analysis of phosphorylated MAPK expression/total MAPK intensity ( n = 6). ### p < 0.001 compared with sham plus vehicle; ∗p 
< 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared with BCCAo plus vehicle. 
Fig. 6. GBE recovers ChAT-positive cholinergic neurons in the basal forebrain following chronic BCCAo. (A) Representative ChAT staining in the basal forebrain. (B) Measure- 
ment of the absolute numbers of ChAT-positive cholinergic neurons ( n = 6). ### p < 0.001 compared with sham plus vehicle; ∗p < 0.05, ∗∗∗p < 0.001 compared with BCCAo 
plus vehicle. Original magniﬁcation was 200 ×. 
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 hat GBE may have exerted anti-inﬂammatory effects via a mecha-
ism involving the inhibition of MyD88-dependent TLR4 signaling. 
Moreover, we investigated the expression of RAGE and Ang-II in
he hippocampus following BCCAo and GBE treatment. RAGE has
een reported to be responsible for the activation of inﬂamma-
ory reactions and has a role in innate immunity ( Yamamoto and
amamoto, 2013 ). In contrast, Ang-II is a multifunctional peptide
hat has an important role in the production of proinﬂammatory
ytokines, including TNF- α, IL-1 β , and IL-6 ( Jia et al., 2012 ). Our
tudies showed that treatment with GBE at a dose of 40 mg/kg
igniﬁcantly decreased hippocampal RAGE and Ang-II levels, thus
ndicating that GBE may regulate proinﬂammatory cytokines by in-
ibiting the expression of RAGE. 
The activation of MAPKs, such as ERK, p38, and JNK, is corre-
ated with the production of inﬂammatory mediators ( Cho et al.,
015 ). Moreover, MAPK activation is considered to represent a pri-
ary consequence of MyD88-dependent TLR signaling ( Kawai and
kira, 2010 ). Consistent with previous reports, hippocampal MAPKs
uch as ERK and p38 were found to be hyperphosphorylated in BC-
Ao rats ( Lee et al., 2013 ). GBE treatment, particularly at a dose
f 40 mg/kg, inhibited the BCCAo-induced phosphorylation of ERK
nd p38, without altering the total MAPK expression. Therefore,
he inhibition of MAPK activation may be another mechanism by
hich GBE suppresses inﬂammation in CCH. 
Finally, our study critically addressed the alterations in cholin-
rgic function. Appropriate functionality of the cholinergic sys-
em is known to be essential for normal cognitive function. Ap-
roximately 40% of VaD patients showed signiﬁcant reductions
n acetylcholine (Ach) levels in the brain, and these alterations
ere thought to be responsible for memory dysfunction ( Perry and
alaria, 2002 ). BCCAo has been reported to decrease the expres-
ion of ChAT, an enzyme for Ach synthesis, in the basal forebrain
f rats ( Choi et al., 2011 ). Thus, the restoration of ChAT expression
ay be a useful therapeutic approach in VaD. Our data showed
hat GBE, particularly at a dose of 40 mg/kg, signiﬁcantly increased
hAT expression in the basal forebrain of BCCAo rats. In addi-
ion, pretreatment with GBE has been shown to inhibit acetyl-
holinesterase activity, which could in turn increase the acetyl-
holine levels ( Baradaran et al., 2012 ). These results readily explain
he previous reports indicating improvements in cognitive function
ollowing GBE administration ( Li et al., 2013 ). Nevertheless, addi-
ional studies are needed to directly observe the relationship be-
ween the effects reported herein and improved cognitive function,
nd furthermore to investigate the intracellular signaling pathways
ctivated by GBE, such as cyclic adenosine monophosphate/protein
inase A-CREB. 
Our research revealed that GBE affected neuroinﬂammation and
he cholinergic system following CCH, but the exact mechanism
nderlying this pathological improvement remains unclear. How-
ver, a recent study reported that the anti-inﬂammatory function
f GBE might involve the enhancement of autophagy. In particular,
reatment with GBE signiﬁcantly induced autophagy in an amyloid
recursor protein-transgenic mouse model of Alzheimer’s disease,
nd reduced the expression of NLRP3, which is a key component of
he inﬂammasome ( Liu et al., 2015 ). Since NLRP3 affects the acti-
ation of proinﬂammatory cytokines ( Schroder and Tschopp, 2010 ),
BE treatment may inhibit inﬂammatory responses. 
onclusion 
Overall, our data provide evidence indicating that GBE improves
CCAo-induced VaD-like pathology by alleviating glial prolifera-
ion, neuroinﬂammation, and cholinergic deﬁcits. Given that CCH
ay damage the hippocampus and white matter in VaD, GBE may
e a promising therapeutic treatment for patients with VaD. onﬂict of interest 
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